Evidence map›Paper›PMID 33036464›Full record

ArticleGenes2020

Characterization of Hormone-Dependent Pathways in Six Human Prostate-Cancer Cell Lines: A Gene-Expression Study.

Andras Franko, Lucia Berti, Alke Guirguis, Jörg Hennenlotter, Robert Wagner, Marcus O Scharpf, Martin Hrabĕ de Angelis, Katharina Wißmiller, Heiko Lickert, Arnulf Stenzl and 5 more

Abstract read
In one paragraph

Article in Genes, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Genomic Characterization of Preclinical Prostate Cancer Cell Line Models.International journal of molecular sciences · 2024
    Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Andras FrankoDepartment of Internal Medicine IV, Division of Diabetology, Endocrinology, and Nephrology, University Hospital Tübingen, 72076 Tübingen, Germany.ORCID 0000-0003-0485-5439
Lucia BertiInstitute for Diabetes Research and Metabolic Diseases of the Helmholtz Centre Munich at the University of Tübingen, 72076 Tübingen, Germany.ORCID 0000-0003-4264-5096
Alke GuirguisDepartment for Diagnostic Laboratory Medicine, Institute for Clinical Chemistry and Pathobiochemistry, University Hospital Tübingen, 72076 Tübingen, Germany.
Jörg HennenlotterDepartment of Urology, University Hospital Tübingen, 72076 Tübingen, Germany.ORCID 0000-0003-3827-6996
Robert WagnerDepartment of Internal Medicine IV, Division of Diabetology, Endocrinology, and Nephrology, University Hospital Tübingen, 72076 Tübingen, Germany.ORCID 0000-0002-6120-0191
Marcus O ScharpfInstitute of Pathology, University Hospital Tübingen, 72076 Tübingen, Germany.
Martin Hrabĕ de AngelisGerman Center for Diabetes Research (DZD), 85764 Neuherberg, Germany.
Katharina WißmillerInstitute of Diabetes and Regeneration Research, Helmholtz Zentrum München, 85764 Neuherberg, Germany.ORCID 0000-0002-0224-7563
Heiko LickertGerman Center for Diabetes Research (DZD), 85764 Neuherberg, Germany.
Arnulf StenzlDepartment of Urology, University Hospital Tübingen, 72076 Tübingen, Germany.ORCID 0000-0003-4207-9928
Andreas L BirkenfeldDepartment of Internal Medicine IV, Division of Diabetology, Endocrinology, and Nephrology, University Hospital Tübingen, 72076 Tübingen, Germany.
Andreas PeterInstitute for Diabetes Research and Metabolic Diseases of the Helmholtz Centre Munich at the University of Tübingen, 72076 Tübingen, Germany.
Hans-Ulrich HäringDepartment of Internal Medicine IV, Division of Diabetology, Endocrinology, and Nephrology, University Hospital Tübingen, 72076 Tübingen, Germany.
Stefan Z LutzDepartment of Internal Medicine IV, Division of Diabetology, Endocrinology, and Nephrology, University Hospital Tübingen, 72076 Tübingen, Germany.
Martin HeniDepartment of Internal Medicine IV, Division of Diabetology, Endocrinology, and Nephrology, University Hospital Tübingen, 72076 Tübingen, Germany.ORCID 0000-0002-8462-3832

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate cancer (PCa), the most incident cancer in men, is tightly regulated by endocrine signals. A number of different PCa cell lines are commonly used for in vitro experiments, but these are of diverse origin, and have very different cell-proliferation rates and hormone-response capacities. By analyzing the gene-expression pattern of main hormone pathways, we systematically compared six PCa cell lines and parental primary cells. We compared these cell lines (i) with each other and (ii) with PCa tissue samples from 11 patients. We found major differences in the gene-expression levels of androgen, insulin, estrogen, and oxysterol signaling between PCa tissue and cell lines, and between different cell lines. Our systematic characterization gives researchers a solid basis to choose the appropriate PCa cell model for the hormone pathway of interest.

Indexed as

AgedAndrogensBiomarkers, TumorEstrogensHumansInsulinMaleOxysterolsProstatic NeoplasmsReceptor, InsulinReceptors, AndrogenReceptors, EstrogenAndrogensAR protein, humanBiomarkers, TumorEstrogensInsulinOxysterolsReceptor, InsulinReceptors, AndrogenReceptors, Estrogenandrogen receptorestrogen receptorgene expressioninsulin receptorprostate cancer

Identifiers

PMID33036464
PMCPMC7599530

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.